Loading company…
PanTera produces actinium-225 for targeted radiotherapy and cancer treatment.
Founded in 2022 and based in Belgium, PanTera focuses on large-scale production of actinium-225 for targeted radiotherapy. The company said it planned to use funding to build a production facility in Belgium. In September 2024, it raised EUR 93 million in Series A funding led by EQT Life Sciences, with PMV, Paladin Capital Group, Korys, Eurazeo, Sck Cen, and Kurma Partners participating.
Funding rounds, investors and people for this company come from licensed data. A free account shows the first rows of each section; an approved contribution opens every profile in full.
Sign in